NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market Tuesday that it will develop a companion diagnostic test for Celgene's Revlimid (lenalidomide), which the firm is developing for diffuse large B-cell lymphoma.

NanoString said that it will develop the in vitro diagnostic assay for use on its nCounter Analysis System. The assay will be used to screen patients who are being enrolled in a pivotal study of Revlimid for the treatment of DLBCL.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.